好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Relationship between Cycling of Traditional Oral Generic Preventive Medications and Patient-Reported Outcomes: US Results from the Chronic Migraine Epidemiology and Outcomes – International Study
General Neurology
P8 - Poster Session 8 (8:00 AM-9:00 AM)
11-009
Evaluate the relationship between the number of traditional oral generic preventive medications (OGPMs) and patient-reported outcomes (PROs) in US respondents of the Chronic Migraine Epidemiology and Outcomes–International (CaMEO-I) study.

OGPMs are often associated with suboptimal efficacy, contraindications, or side effects, leading to high discontinuation rates and cycling through multiple medications.

CaMEO-I was a cross-sectional, web-based survey conducted in 2021-2022 in six countries. Respondents with ICHD-3 migraine were stratified by self-reported history of ever using 1, 2, or ≥3 OGPMs; those who had used branded preventive medication(s) were excluded. Associations between OGPM use and migraine-related disability (Migraine Disability Assessment Scale [MIDAS] Grade III or IV), cognitive impairment (Migraine Cognitive Impairment Questionnaire [MCIQ]), quality of life (Migraine Specific Quality of Life [MSQ]), allodynia (ASC-12), and functional disability (FDS) were assessed. Linear trend tests, using chi-square for categorical variables and ANOVA for continuous variables, were conducted to determine if the severity of outcomes increased with number of OGPMs.
In total, 19.6% (472/2404) of US respondents with migraine had ever used at least 1 OGPM (mean [SD] age 43.5 [12.69] years, 72.2% female). Of these, 36.0% (170/472) had used 1 OGPM, 22.9% (108/472) had used 2 OGPMs, and 41.1% (194/472) had used ≥3 OGPMs. Cycling OGPMs was associated with greater disability on MIDAS (1: 54.1% [73/170], 2: 67.6% [73/108], ≥3: 71.6% [139/194]; p=0.024), greater cognitive impairment on MCIQ (1: 67.6% [115/170], 2: 70.4% [76/108], ≥3: 77.8% [151/194], p=0.029) and reduced score on the MSQ role function restrictive domain (mean [SD] 1: 56.9 [22.90]; 2: 53.2 [20.95]; 3: 46.3 [22.51]; p<0.001]). Cycling OGPMs was also associated with increased allodynia and reductions in the performance of daily activities and on MSQ role function preventive and emotional function domains.
Cycling through OGPMs was associated with greater disability, higher cognitive impairment, and decreased QoL.
Authors/Disclosures
Kristina M. Fanning, PhD (MIST Reserach)
PRESENTER 		The institution of Dr. Fanning has received research support from Abbvie. The institution of Dr. Fanning has received research support from NYC Langone Health . The institution of Dr. Fanning has received research support from Uiversity of SC - Irvine. The institution of Dr. Fanning has received research support from AESARA.
Dawn C. Buse, PhD (Dawn C. Buse, PhD) Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranicsa. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.
Fumihiko Sakai, MD Dr. Sakai has nothing to disclose.
Manjit Matharu (University College London) The institution of Manjit Matharu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. The institution of Manjit Matharu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Salvia. The institution of Manjit Matharu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie. The institution of Manjit Matharu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. The institution of Manjit Matharu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. The institution of Manjit Matharu has received research support from Abbott. The institution of Manjit Matharu has received research support from EDS Society. The institution of Manjit Matharu has received research support from Medtronic. Manjit Matharu has received intellectual property interests from a discovery or technology relating to health care.
Pranav Gandhi Pranav Gandhi has received personal compensation for serving as an employee of AbbVie. Pranav Gandhi has stock in AbbVie Inc.
Brett Dabruzzo, PharmD (AbbVie Medical Affairs) Dr. Dabruzzo has received personal compensation for serving as an employee of AbbVie. Dr. Dabruzzo has stock in AbbVie.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.